The Postpartum Depression Drug Market is estimated to be valued at US$ 6.671 Billion In 2022 and is expected to exhibit a CAGR of 30.25% over the forecast period 2022-2029, as highlighted in a new report published by Coherent Market Insights.
Postpartum depression (PPD) is a mood disorder that can affect women after childbirth. It is characterized by feelings of extreme sadness, anxiety, and exhaustion that may interfere with daily activities. PPD is estimated to affect between 15-20% of new mothers and is most common during the first three to four months after delivery. Currently, selective serotonin reuptake inhibitors (SSRIs) such as sertraline, paroxetine and fluoxetine are predominantly used in the pharmacological management of PPD.
The postpartum depression drug market is expected to witness significant growth over the forecast period, owing to increasing awareness about PPD and launch of novel therapies. According to Postpartum Support International, majority of women do not recognize symptoms of PPD or seek treatment due to lack of awareness. However, increasing public health initiatives raising awareness about this condition is expected to propel the market growth. Additionally, launch of emerging therapies with improved efficacy and safety profiles is further anticipated to drive the market. For instance, in March 2021, Sage Therapeutics Inc. received approval from the U.S. FDA for Zulresso (brexanolone) CIV injection, which is the first drug to specifically treat postpartum depression. It is administered as a single 60-hour intravenous infusion in a certified healthcare facility under the REMS program.
Strength: The market has witnessed significant growth in research and development leading to advances in diagnostics and treatment. Many large pharmaceutical companies have strong drug pipelines. Growing awareness about postpartum depression and its treatment options.
Weakness: Postpartum depression often goes undiagnosed. Social stigma associated with mental illness prevents many from seeking help. Higher treatment costs pose affordability challenges in developing countries.
Opportunity: Untapped growth opportunities exist in developing nations with large populations and increasing healthcare spending. Digital health tools and telepsychiatry can improve access to therapy in remote areas.
Threats: Stringent regulations for the approval of new drugs increase time and costs. Side effects of drugs can lead to noncompliance. Emergence of alternative treatment methods like psychotherapy, exercise and herbal medicines.
The global Postpartum Depression Drug Market is expected to witness high growth, exhibiting CAGR of 30.25% over the forecast period, due to increasing awareness initiatives being undertaken by governments and nonprofit organizations.
North America currently dominates the global market owing to strong healthcare infrastructure and availability of advanced treatment options. Asia Pacific is projected to witness the fastest growth due growing cases of PPD, improving access to healthcare services and rising healthcare expenditure in major Asian countries.
Key players operating in the Postpartum Depression Drug market are Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd. Sage Therapeutics Inc. is amongst the leading players in developing novel drugs for treating postpartum depression.